Volex plc
VLX.L · LSE
Market closed511.00-12.00 (-2.29%)
Key statistics
Previous close523.00
Open529.00
Day high529.00
Day low507.00
52-week high710.00
52-week low325.00
Market cap938.49M
Volume898.24K
Average volume1.25M
P/E ratio19.27
Forward P/E—
EPS0.27
Dividend yield+0.90%
Market context
Why it moved
VLX.L declined amid broader sector pressure and a lack of positive catalysts, as market research reports highlighting the modest size of the Heparin-Induced Thrombocytopenia market—where the company's pipeline drug VLX-1005 is still in Phase II trials—may have weighed on investor sentiment regarding near-term revenue potential.
What is happening
Recent company-specific developments and publisher coverage.
Law360 · July 16, 2026Components Maker Volex Buys Remainder Of Kepler For $90MInvesting.com · July 14, 2026Volex acquires full ownership of Kepler Signaltek for $89.4mMarketBeat · July 14, 2026Volex (LON:VLX) Receives "Buy" Rating from Berenberg Bankmarketscreener.com · July 14, 2026Volex plc acquired the remaining 64.30% stake in Kepler SignalTek Ltd for $89.4 million. Mt Newswire · July 14, 2026Volex Cuts Size of Stock Buyback Program Mt Newswire · June 25, 2026Volex to List Shares on London Bourse's Main Market on July 24 Mt Newswire · April 22, 2026Volex Targets Medium-term Revenue of $2 Billion Mt Newswire · April 7, 2026Update: Volex Kicks Off Up to GBP40 Million Share Repurchase Program Mt Newswire · April 7, 2026Volex Confirms Listing Move to London's Main Market Mt Newswire · March 25, 2026Volex Expects FY26 Results to Exceed Market Estimates Mt Newswire · October 16, 2025Volex Flags Fiscal H1 Organic Revenue Growth